Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure
Treating multiple myeloma with precision: treatment benefit of ixazomib-based therapy in patients with high-risk cytogenetic abnormalities
The underestimated role of bone marrow T cells as important predictor for treatment response and survival in acute myeloid leukemia
Gilteritinib plus CUDC-907 – A Novel Therapeutic Combination with The Ability to Overcome Drug Resistance
In this study, we showed that combining the second-generation FLT3 inhibitor gilteritinib with the dual PI3K/HDAC inhibitor CUDC-907 synergistically improved anti-leukemic activity against FLT3-ITD acute myeloid leukemia (AML) – and that each agent reciprocally overcame resistance to the other drug.
In a proof-of-principle study published in Blood Cancer Journal, we showed that human CAR T cells can be generated within the host upon injecting an Adeno-associated virus (AAV) vector carrying the CAR gene, which we call AAV delivering CAR gene therapy (ACG).
Chimeric antigen receptor (CAR)-T cell therapy is a new treatment option for certain cancers whose use in clinical practice presents novel challenges and opportunities. Here we highlight a review outlining some limitations and potential strategies to overcome the limitations of CAR-T cell therapy.
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B-cell lymphoma
Lenalidomide has moderate activity in relapsed or refractory diffuse large B-cell lymphoma. Its efficacy may be improved by combination with chemotherapy.